Loading…
Generate Biomedicines, Inc. is projected to rise to $14.04 by 2027, a +7% move from its current price of $13.08. GENB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $12.40 | $13.07 | $13.79 | -0.05% |
| May 30 | $12.12 | $13.07 | $14.09 | -0.10% |
| May 31 | $11.91 | $13.06 | $14.32 | -0.15% |
| Jun 1 | $11.73 | $13.05 | $14.52 | -0.21% |
| Jun 2 | $11.58 | $13.05 | $14.70 | -0.26% |
| Jun 3 | $11.45 | $13.04 | $14.86 | -0.31% |
| Jun 4 | $11.32 | $13.03 | $15.00 | -0.36% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.32 | $13.03 | $15.00 | -0.36% |
| Week 2 | $10.64 | $12.99 | $15.85 | -0.72% |
| Week 3 | $10.14 | $12.94 | $16.51 | -1.07% |
| Week 4 | $9.73 | $12.89 | $17.09 | -1.43% |
| Week 5 | $9.38 | $12.85 | $17.60 | -1.78% |
| Week 6 | $9.07 | $12.80 | $18.07 | -2.13% |
| Week 7 | $8.79 | $12.75 | $18.51 | -2.49% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Generate Biomedicines, Inc. operates in the Healthcare sector and is active in generative biology, using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development and has product candidates including GB-0895, GB-4362, and GB-5267 in its portfolio.
It also develops the Generate Platform, designed to integrate computational innovation with scalable biohardware to address therapeutic challenges beyond traditional technologies. The company was incorporated in 2018 and is based in Somerville, Massachusetts.
GENB is trading at $13.34, with a market capitalization of $1.71B and a rank of 2141.
The 2026 forecast shows a min of $11.21, an avg of $13.34, and a max of $18.04, with neutral sentiment.
Over the longer term, the model projects a bullish trajectory, with the average price rising to $30.54 by 2030 and $172.52 by 2050, while the maximums reach $62.16 in 2030 and $396.79 in 2050; ROI grows from 129 in 2030 to 441.3 by 2040 and 1193.2 by 2050.
A major floor 25.8% below — a decisive break under it would weaken the trend.
The nearest floor, 7.3% below — buyers have tended to step in here.
The nearest ceiling, 24.0% above — a clean break opens room to run.
A major ceiling 36.9% above — clearing it would confirm fresh momentum.
Key GENB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GENB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.59 | Sell | $13.55 | Sell |
| MA 10 | $14.11 | Sell | $13.79 | Sell |
| MA 20 | $14.08 | Sell | $13.78 | Sell |
| MA 50 | $13.05 | Buy | $13.34 | Sell |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.88 | Neutral |
| Stoch RSI (14) | 14.74 | Buy |
| CCI (20) | -62.78 | Neutral |
| Williams %R (14) | -82.63 | Info |
| MACD (12,26,9) | -0.21 | Sell |
| ROC (12) | -4.25 | Sell |
| Bollinger %B (20,2) | 0.29 | Neutral |
| Stochastic %K (14) | 17.37 | Buy |
| TRIX (15) | 0.42 | Buy |
| Awesome (5,34) | 0.18 | Buy |
| Ultimate (7,14,28) | 36.02 | Neutral |
| Momentum (10) | -2.41 | Sell |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 13.61 | Sell |
| ADX (14) | 12.27 | Neutral |
| ATR (14) | 0.73 | Info |
The 30-day technical picture is NEUTRAL.
RSI(14) is 50 and the 50-day simple moving average (SMA50) is $13.03. There is no SMA200 provided in the data.
The 30-day range spans from $9.29 to $19.15, with a support level at $12.12 and a resistance at $16.22. Annualized volatility is 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $11.21 | $13.08 | $17.64 | 0% | Neutral | |
| $9.06 | $14.04 | $23.51 | +7% | Neutral | |
| $10.04 | $17.22 | $31.28 | +32% | Bullish | |
| $12.19 | $22.89 | $44.22 | +75% | Bullish | |
| $13.73 | $28.11 | $57.13 | +115% | Bullish | |
| $13.51 | $30.02 | $63.71 | +129% | Bullish | |
| $14.90 | $33.11 | $73.02 | +153% | Bullish | |
| $13.98 | $31.06 | $70.87 | +137% | Bullish | |
| $13.57 | $30.15 | $69.36 | +131% | Bullish | |
| $19.01 | $42.25 | $97.17 | +223% | Bullish | |
| $28.41 | $63.12 | $145.18 | +383% | Bullish | |
| $65.52 | $145.59 | $334.86 | +10.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $11.21 | $13.08 | $15.67 | +0.00% |
| June 2026 | $10.16 | $12.45 | $15.98 | -4.82% |
| July 2026 | $9.92 | $12.48 | $16.62 | +0.26% |
| August 2026 | $9.96 | $12.79 | $17.50 | +2.46% |
| September 2026 | $9.19 | $12.00 | $16.79 | -6.13% |
| October 2026 | $8.42 | $11.18 | $15.95 | -6.85% |
| November 2026 | $8.62 | $11.61 | $16.85 | +3.84% |
| December 2026 | $8.77 | $11.97 | $17.64 | +3.06% |
Click any year to see its month-by-month GENB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Generate Biomedicines, Inc.'s 2026 outlook centres on $13.08, within a $11.21 to $17.64 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, GENB could reach as high as $23.51, with a base case around $14.04 and support toward $9.06 — roughly +7% from $13.08. Price action looks broadly range-bound.
Expect GENB to range from $10.04 to $31.28 through 2028. The $17.22 average target implies a +32% move from current prices. That is up +23% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The GENB price prediction for 2029 points to an average of $22.89 (low $12.19, high $44.22) — a potential gain of +75% on today's $13.08. Momentum favours further upside here.
In 2030, GENB is projected to trade between $13.73 and $57.13, averaging $28.11 — a potential gain of +115% from today's $13.08. That is up +23% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Generate Biomedicines, Inc.'s 2031 outlook centres on $30.02, within a $13.51 to $63.71 range. That is up +7% on the projected 2030 average. That marks a +129% change versus current levels. Momentum favours further upside here.
By 2032, GENB could reach as high as $73.02, with a base case around $33.11 and support toward $14.90 — roughly +153% from $13.08. Buyers look set to stay in control over this stretch.
Expect GENB to range from $13.98 to $70.87 through 2033. The $31.06 average target implies a +137% move from current prices. That is -6% versus the projected 2032 average. Momentum favours further upside here.
The GENB price prediction for 2034 points to an average of $30.15 (low $13.57, high $69.36) — a potential gain of +131% on today's $13.08. Buyers look set to stay in control over this stretch.
In 2035, GENB is projected to trade between $19.01 and $97.17, averaging $42.25 — a potential gain of +223% from today's $13.08. That is up +40% on the projected 2034 average. Momentum favours further upside here.
Generate Biomedicines, Inc.'s 2040 outlook centres on $63.12, within a $28.41 to $145.18 range. That is up +49% on the projected 2035 average. That marks a +383% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, GENB could reach as high as $334.86, with a base case around $145.59 and support toward $65.52 — roughly +10.1x from $13.08. Momentum favours further upside here.
Investing $1,000 in GENB today (≈ 76.452599 GENB) could be worth
$11,130.67
+$10,130.67 (+1013%) by 2050 · US Dollar
Based on the average projected GENB price of $145.59 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GENBwould be worth at today's price.
$1,000 invested in GENB on Feb 27, 2026 (≈ 79.051386 GENB) would be worth
$1,033.99
+$33.99 (+3.4%) today · 1.03× · US Dollar
Based on a GENB entry price of $12.65 vs. today's $13.08.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.02 | $1,004.61 | +0.5% |
| 1 month ago | $12.45 | $1,050.6 | +5.1% |
| 3 months ago | $12.65 | $1,033.99 | +3.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GENB forecast.
Our base-case forecast reaches $26.00 around 2030.
Implied market cap at $26.00: $3.33B
The multi-year forecast shows a bullish trajectory after 2026, with 2027–2032 continuing to trend higher and 2033–2035 maintaining a bullish outlook. The 2027 average is $14.61, 2028 $18.44, 2029 $24.77, and 2030 $30.54, with corresponding ROIs of 9.5, 38.3, 85.7, and 129 respectively.
Beyond 2030, the forecast continues to rise: 2031 avg $32.84, 2032 $36.31, 2033 $34.16, 2034 $33.50, and 2035 $47.92. By 2040, the average price is projected at $72.20 and by 2050 at $172.52, with max values of $166.07 and $396.79 respectively. ROI expands to 146.2 (2031), 172.2 (2032), 156 (2033), 151.1 (2034), 259.3 (2035), 441.3 (2040), and 1193.2 (2050).
The sentiment is consistently BULLISH for the longer horizon, with increasing upside noted in each period.
These are estimates and not guarantees; actual results may differ.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $30.54, a min of $14.88, and a max of $62.16, with a bullish sentiment and an ROI of 129.
The forecast shows a bullish path from 2027 onward with rising average prices (e.g., $14.61 in 2027, $18.44 in 2028, $24.77 in 2029, $30.54 in 2030, and $172.52 in 2050) and increasing ROI (up to 1193.2 by 2050). However, these are estimates and not guarantees.
Yes. The forecast max values exceed $100, with 2035 max $110.23, 2040 max $166.07, and 2050 max $396.79.
The current price is $13.34 and the market capitalization is $1.71B.
The 30-day picture is NEUTRAL, with RSI(14) at 50, SMA50 at $13.03, a 30-day range of $9.29 to $19.15, a support at $12.12, and a resistance at $16.22; annualized volatility is 100%.
Generate Biomedicines, Inc. Community Discussion
0Share your Generate Biomedicines, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.